7-Aminonimetazepam
(Synonyms: Ro 05-4318) 目录号 : GC41175An Analytical Reference Material
Cas No.:4959-16-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
7-Aminonimetazepam is an analytical reference material that is structurally categorized as a benzodiazepine.[1] It is a metabolite of nimetazepam that can be detected in urine specimens following nimetazepam use. The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications. This product is a qualified Reference Material (RM) that has been manufactured and tested to meet ISO/IEC 17025 and ISO Guide 34 guidelines.
Reference:
[1]. Wang, K.-C., Cheng, M.-C., Hseieh, C.-L., et al. Determination of nimetazepam and 7-aminonimetazepam in human urine by using liquid chromatography-tandem mass spectrometry. Forensic Sci. Int. 224(1-3), 84-89 (2013).
| Cas No. | 4959-16-4 | SDF | |
| 别名 | Ro 05-4318 | ||
| 化学名 | 7-amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one | ||
| Canonical SMILES | NC1=CC(C(C2=CC=CC=C2)=NC3)=C(C=C1)N(C)C3=O | ||
| 分子式 | C16H15N3O | 分子量 | 265.3 |
| 溶解度 | A 100 µg/ml or 1 mg/ml solution in acetonitrile | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7693 mL | 18.8466 mL | 37.6932 mL |
| 5 mM | 0.7539 mL | 3.7693 mL | 7.5386 mL |
| 10 mM | 0.3769 mL | 1.8847 mL | 3.7693 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Determination of nimetazepam and 7-Aminonimetazepam in human urine by using liquid chromatography-tandem mass spectrometry
Forensic Sci Int 2013 Jan 10;224(1-3):84-9.PMID:23245766DOI:10.1016/j.forsciint.2012.11.001.
We report determination of metabolites of popular drugs of abuse, including nimetazepam and nitrazepam, in urine by using liquid chromatography/mass spectrometry. Nimetazepam and its metabolites, 7-Aminonimetazepam and nitrazepam, were extracted by solid-phase extraction using a DAU cartridge. An ammonium acetate buffer solution (pH 4) and a Luna polar-RP column were selected as the mobile and stationary phase, respectively, for liquid chromatography. Mass spectrometry was used for analysis and was optimized for operation in the positive mode for all analytes. The urine specimens were screened for the presence of nimetazepam and its metabolites nitrazepam and 7-Aminonimetazepam at a concentration of 0.1ng/mL. Presence of 7-Aminonimetazepam in the urine was an indicator of the subject being a probable abuser of nimetazepam.
An autopsy case of death by combined use of benzodiazepines and diphenidine
Soud Lek 2017 Winter;62(4):40-43.PMID:29227117doi
We present an autopsy case involving benzodiazepines and diphenidine. Quantitative toxicological analysis showed concentrations of 7-aminoflunitrazepam (a flunitrazepam metabolite), 7-Aminonimetazepam (a nimetazepam metabolite), chlorpheniramine and diphenidine in femoral blood of 0.086 µg/ml, 0.027 µg/ml, 0.066 µg/ml, and 0.073 µg/ml, respectively. Death was attributed to combined toxicity due to the influence of multiple drug interactions.
Simultaneous Quantitation of Seven Phenethylamine-Type Drugs in Forensic Blood and Urine Samples by UHPLC-MS-MS
J Anal Toxicol 2022 Mar 21;46(3):246-256.PMID:33575738DOI:10.1093/jat/bkab014.
Abuse of new psychoactive substances (NPS) has become a health and social issue of global concern. p-Methoxyamphetamine (PMA)/p-methoxymethamphetamine (PMMA) with fluoro- or chloro-derivatives of amphetamine and methamphetamine were among the most common drugs found in specimens from fatal cases in Taiwan during the January 2011 to December 2018 period. A liquid-liquid extraction sample preparation protocol with highly sensitive ultra-high performance liquid chromatography-tandem mass spectrometry approach was developed for the simultaneous analysis of seven phenethylamine-type drugs-PMA, PMMA, p-methoxyethylamphetamine, 4-fluoroamphetamine (4-FA), 4-fluoromethamphetamine (4-FMA), 4-chloroamphetamine (4-CA) and 4-chloromethamphetamine (4-CMA)-in postmortem blood and urine specimens. Separation by liquid chromatography was performed by Agilent Zorbax SB-Aq column. Tandem mass spectrometry was operated in Agilent Jet Stream Technology electrospray ionization in positive-ion multiple reaction monitoring mode. An analytical methodology was evaluated using drug-free blood and urine after fortification with 100-2,000 ng/mL of the seven target analytes. Average extraction recoveries were >80%; slightly higher ion suppression was observed for PMA and 4-CA; intra-/inter-day precision (% coefficient of variation) and accuracy were in the ranges of 0.52-12.3% and 85-110%, respectively. Limit of detection and lower limit of quantitation for these seven analytes were both in the 0.5-5 ng/mL range. Interference and carryover were not significant. This relatively simple methodology was found effective and reliable for routine identification and quantitation of these seven analytes in postmortem and antemortem blood and urine specimens received in 2018. Analytical data obtained from these actual cases indicated the following: (i) compared to findings reported during the 2007-2011 period, the use of substituted phenethylamine-type drugs decreased in 2018; (ii) ketamine and 7-Aminonimetazepam (the main metabolite of nimetazepam) were the most common co-ingested substances in specimens containing PMA/PMMA, 4-FA/4-FMA, or 4-CA/4-CMA; and (iii) in drug fatalities, the concentration of PMA was significantly higher than the concentration of PMMA in both urine and blood, while the reverse was true in urine specimens from antemortem cases.
The occurrence of alcohol/drugs by toxicological examination of selected drivers in Hong Kong
Forensic Sci Int 2017 Jun;275:242-253.PMID:28412576DOI:10.1016/j.forsciint.2017.03.022.
The study is to investigate the extent of alcohol/drug(s) use among selected drivers, i.e. fatally injured drivers from traffic accidents (2006-2015), drink driving (2006-2015) and drug driving (2010-2015) cases, in Hong Kong. Between 2006 and 2015, specimens from a total of 223 fatally injured drivers were received for toxicological examination. Except for one driver, all other drivers with positive findings were male. Alcohol and/or drugs were detected in 60 (27%) cases where alcohol alone was detected in 40 cases (18%) while drugs with/without alcohol were detected in 20 cases (9%). A decreasing trend is observed for cases with blood/breath alcohol concentrations above the prescribed limits in both fatally injured drivers and drivers from drink driving cases in 2006-2015. Out of the 20 cases with positive findings in drugs, 8 of them were found with alcohol in which only one case found at level above the prescribed limit. The frequency of drugs encountered that are known to affect driving in blood is 31, representing an average of about 1.7 drugs per individual. Ketamine was the most frequently detected drug in fatally injured drivers. Sedatives/hypnotics (i.e. diazepam/nordiazepam, midazolam, 7-Aminonimetazepam, 7-aminonitrazepam and zopiclone), morphine/monoacetylmorphine, cocaine/benzoylecgonine, methamphetamine, methadone and codeine were also detected. There has been a sharp increase in the submission of blood/urine specimens for toxicological analysis related to drug driving cases since 2010 with a total of 48 cases received in 2010-2011. With the introduction of legislative amendment of drug driving law since 2012, 154 cases were received in 2012-2015. The positive rates for drug driving cases examined were found to be 90% (43 out of 48 cases) in 2010-2011 and 89% (137 out of 154 cases) in 2012-2015. Drivers with single drug use were more frequently detected (40 cases in 2010-2011 and 82 cases in 2012-2015) than multiple drug use (3 cases in 2010-2011 and 55 cases in 2012-2015) but an increase in the use of more than one drug in driving population is noted. Ketamine was detected in the majority of cases (34 cases in 2010-2011 and 104 cases in 2012-2015). However, drug driving cases in recent years revealed that increase usages of methamphetamine, cocaine and zopiclone were observed. The mean, median and range of ketamine concentrations for 134 blood samples taken from drivers in drug driving cases were 0.34, 0.27, 0.01-1.8μg/mL respectively.
Simultaneous quantification of urine flunitrazepam, nimetazepam and nitrazepam by using liquid chromatography tandem mass spectrometry
Clin Chim Acta 2013 May;420:134-9.PMID:23085494DOI:10.1016/j.cca.2012.10.023.
Background: Benzodiazepines are used in hypnotics, sedation, and anti-anxiety. Recently liquid chromatography tandem mass spectrometry (LC-MS/MS) has been vastly developed for drug analysis in biological samples. Methods: We developed and validated a LC-MS/MS method for simultaneous quantification of flunitrazepam (FM2), nimetazepam and nitrazepam levels in 87 benzodiazepine positive human urine specimens by enzyme immunoassay. Deuterated analogues were used as internal standard. Results: The limits of quantification were found to be 0.25, 2.5, 5, 5 and 1ng/ml for FM2, 7-aminoFM2, nimetazepam, 7-amino-nimetazepam and nitrazepam, respectively. The intraday and inter-day CVs ranged from 0.6 to 4.6% and 1.2-9.4%, respectively. The within-day accuracy ranged from 80.8 to 108.7% and the between-day accuracy ranged from 80.5 to 118.0%. The recovery rate ranged from 70.5 to 96.7% for five different analytes. A group of 34 urine samples previously gas chromatography-mass spectrometry determined to contain 7-aminoFM2 was analyzed by this new LC-MS/MS approach. Quantitative data produced by both methods agreed well. Conclusions: The LC-MS/MS method has proved to be robust and specific for the quantification of FM2, nimetazepam and nitrazepam in urine samples. This study also confirmed that nitrazepam and 7-Aminonimetazepam are the metabolic products of nimetazepam.